New York-based drugmaker Pfizer says it will reduce its global workforce by 6,000 employees over the next several years.
The move is part of the company’s acquisition of rival drug maker Wyeth.
Pfizer plans to end operations at eight manufacturing sites and reduce operations at another six facilities. The biggest U.S. cuts will come to the Pearl River, New York, facility. Pfizer plans to end production there of tablets and capsules, as well as biotechnology and other consumer healthcare products.
Vaccine research and development will not be impacted at the Pearl River location.